Clinical trials: Individual Difference
Healthy
A Study in Healthy People to See How Zongertinib is Taken up Into the Blood When Given as Tablets Made by Two Different Manufacturers
The main objective of this trial is to establish the bioequivalence of zongertinib tablet from manufacturer 1 (Test, T) compared with zongertinib tablet from manufacturer 2 (reference, R) following oral administration.
- Trial name
- NCT06360081
- Testing
- Zongertinib manufacturer 1, Zongertinib manufacturer 2
- Where
- Germany
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Bronchiectasis
A Study to Test Whether Different Doses of BI 1291583 Help People With Bronchiectasis
This study is open to adults with bronchiectasis. People can join the study if they produce sputum and have a history of flare-ups (also called exacerbations).
- Trial name
- NCT05238675
- Testing
- BI 1291583
- Where
- 112 sites in United States, Australia and 21 more
- Volunteers
- 322 people
- Sponsor
- Boehringer Ingelheim
Solid Tumors
A Study to Test Different Doses of BI 1831169 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)
This study is open to adults with different types of advanced cancer (solid tumors) that are accessible for injection and/or biopsy.
- Trial name
- NCT05155332
- Testing
- BI 1831169, anti-PD-1 antibody
- Where
- 33 sites in United States, Australia and 8 more
- Volunteers
- 190 people
- Sponsor
- Boehringer Ingelheim
Osteoarthritis, Knee and Hip
Change in Patient Reported Outcomes and Wish for Joint Surgery
Aim To investigate associations between within-person change in patient reported outcomes (PROMs) and wish for joint surgery during up to 12-month participation in a digital first-line intervention for knee and hip osteoarthritis…
- Trial name
- NCT05455177
- Testing
- Digital first-line intervention for osteoarthritis including exercise and education
- Where
- Sweden
- Volunteers
- 14,018 people
- Sponsor
- Joint Academy
Geographic Atrophy
A Study to Test How Well Different Doses of BI 771716 Are Tolerated by People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy
This study is open to adults with geographic atrophy, an advanced form of age-related macular degeneration. People can join the study if they are at least 50 years old.
- Trial name
- NCT06006585
- Testing
- BI 771716
- Where
- 9 sites in United States
- Volunteers
- 20 people
- Sponsor
- Boehringer Ingelheim
Solid Tumors
A Study to Test Different Doses of BI 3923948 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)
This study is open to adults aged 18 and over or above legal age with different types of recurrent advanced cancer (solid tumors) that have spread to other parts of the body and that are accessible for injection and biopsy.
- Trial name
- NCT07395258
- Testing
- BI 3923948, Ezabenlimab
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Boehringer Ingelheim
Heart Failure
A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy
This study will look into how CDR132L (a potential new medicine) works on the structure and function of the heart in people living with heart failure.
- Trial name
- 8212-Preserved (NCT06979362)
- Testing
- CDR132L
- Where
- 118 sites in United States, Canada and 7 more
- Volunteers
- 200 people
- Sponsor
- Novo Nordisk A/S
Healthy
A Study in Healthy People to Test How Zongertinib is Taken up in the Body When Given as Tablets Made by Two Different Manufacturers With or Without Food
The main objective of this trial is to establish the bioequivalence of Zongertinib tablets from two different manufacturers following oral administration.
- Trial name
- NCT07789028
- Testing
- Zongertinib, Formulation A, reference product, Zongertinib Formulation B, test product
- Where
- Germany
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Rabies
Clinical Trial of Freeze-dried Human Rabies Vaccine (Without Serum Vero Cells)
This study was intended to explore the safety and immunogenicity of the test vaccine compared to the control vaccine. The trial consisted of two phases. Phase I used an open-ended design.
- Trial name
- NCT05969626
- Testing
- 5-dose group of test vaccine, 5-dose group of control vaccine, 4-dose A group of test vaccine
- Where
- 4 sites in China
- Volunteers
- 2,460 people, healthy volunteers welcome
- Sponsor
- Ningbo Rongan Biological Pharmaceutical Co., Ltd.
Healthy, Metabolic Dysfunction-associated Steatohepatitis
A Study to Test How Well Different Doses of BI 3804379 Are Tolerated by Healthy People and Patients With Metabolic Dysfunction-associated Steatohepatitis (MASH)
The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics (PKs) of BI 3804379 in healthy male and female participants and in stable patients with advanced liver fibrosis due to MASH following…
- Trial name
- NCT06575400
- Testing
- BI 3804379
- Where
- Belgium
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Solid Tumors
A Study to Test How Well Different Doses of BI 1831169 in Combination With an Anti-PD1 Antibody Are Tolerated in Japanese People With Different Advanced Cancers
This study is open to Japanese adults with different types of advanced cancer (solid tumors). People can join the study if their cancer has spread, and previous treatments were not successful or no treatments exist.
- Trial name
- NCT07176975
- Testing
- BI 1831169, nivolumab
- Where
- Japan
- Volunteers
- 46 people
- Sponsor
- Boehringer Ingelheim
Hepatic Insufficiency
A Study to Test How Iclepertin is Taken up in the Blood of People With and Without Liver Problems
This study is open to people with and without liver problems. People can join the study if they are 18 to 79 years of age and have a body mass index (BMI) between 18.5 and 35 kg/m2.
- Trial name
- NCT05731895
- Testing
- Iclepertin
- Where
- Germany
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Neuroendocrine Neoplasms
DAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers
This study is open to adults aged 18 and older or above legal age who have a specific type of advanced neuroendocrine cancer (NEC). Their tumours must be positive for a marker called DLL3.
- Trial name
- NCT06132113
- Testing
- BI 764532, Carboplatin, Etoposide
- Where
- 21 sites in United States, Belgium and 6 more
- Volunteers
- 65 people
- Sponsor
- Boehringer Ingelheim
Healthy
A Study in Healthy People to Compare Two Different Sifrol® Tablets
The main objective of this trial is to establish the bioequivalence of Sifrol® tablets manufactured at two different sites.
- Trial name
- NCT06457204
- Testing
- Pramipexole manufactured in Ingelheim, Pramipexole manufactured in Ennigerloh
- Where
- Germany
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Neoplasm Metastasis, Non-Small Cell Lung Cancer
Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)
The study has 2 parts. The first part is open to adults with different types of advanced cancer (solid tumours with changes in the HER2 gene) for whom previous treatment was not successful.
- Trial name
- NCT04886804
- Testing
- zongertinib
- Where
- 85 sites in United States, Australia and 16 more
- Volunteers
- 554 people
- Sponsor
- Boehringer Ingelheim
Hepatic Insufficiency
A Study to Test How BI 1015550 is Taken up in the Blood of People With and Without Liver Problems
This study is open to adults aged 18 years and older. People without liver problems and people who have mild or moderate liver problems can join the study.
- Trial name
- NCT05661344
- Testing
- BI 1015550
- Where
- Germany
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Gastrointestinal Cancer, Lung Cancer
A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Advanced Cancer (Solid Tumours) Positive for B7-H6
This is a study in adults from Asia with different types of advanced cancer (solid tumours). People can join the study if they have cancer of the stomach, large bowel and rectum, pancreas, liver, head and neck or non-small cell…
- Conditions
- Gastrointestinal Cancer, Lung Cancer, Pancreatic Cancer, Colorectal Cancer
- Trial name
- NCT06091930
- Testing
- BI 765049, Ezabenlimab
- Where
- 3 sites in Japan
- Volunteers
- 21 people
- Sponsor
- Boehringer Ingelheim
Solid Tumors, KRAS Mutation
A Study to Test Different Doses of BI 3011441 in Japanese People With Different Types of Advanced Cancer (NRAS/KRAS Mutation Positive)
This study is open to Japanese adults with different types of advanced cancer that are positive for NRAS/KRAS mutations. This is a study in people for whom previous treatment was not successful or no standard treatment exists.
- Trial name
- NCT04742556
- Testing
- BI 3011441
- Where
- 3 sites in Japan
- Volunteers
- 15 people
- Sponsor
- Boehringer Ingelheim
Diabetic Nephropathies
A Study to Test the Effect of Different Doses of BI 685509 on Kidney Function in People With Diabetic Kidney Disease
This study is open to adults with diabetic kidney disease. The purpose of the study is to find out whether a medicine called BI 685509 improves kidney function. Three different doses of BI 685509 are tested in this study.
- Trial name
- NCT04750577
- Testing
- BI 685509
- Where
- 78 sites in United States, Argentina and 14 more
- Volunteers
- 243 people
- Sponsor
- Boehringer Ingelheim
Renal Insufficiency, Healthy
A Study to Test How BI 1015550 is Taken up in the Blood of People With and Without Kidney Problems
This study is open to adults aged 18 years and older. People without kidney problems and people who have moderate or severe kidney problems can join the study.
- Trial name
- NCT05718648
- Testing
- BI 1015550
- Where
- Germany
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim